Thyroid cancer diagnostic company Veracyte files for a $75 million IPO

By
A A A

Veracyte, which is developing molecular diagnostic tests for thyroid cancer, filed on Friday with the SEC to raise up to $75 million in an initial public offering. The San Francisco, CA-based company, which was founded in 2006 and booked $17 million in sales for the 12 months ended June 30, 2013, plans to list on the NASDAQ under the symbol VCYT. Veracyte initially filed confidentially on August 13, 2013. Morgan Stanley and Leerink Swann are the joint bookrunners on the deal. No pricing terms were disclosed.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks:

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

33,110,376
  • $113.99 ▲ 1.77%
25,034,179
    $17.98 unch
24,486,872
  • $7.41 ▲ 2.07%
20,864,535
  • $7.39 ▼ 2.76%
18,600,501
  • $8.30 ▼ 0.36%
17,530,211
  • $8.14 ▲ 3.17%
17,299,208
  • $93.79 ▲ 2.74%
14,669,760
  • $25.78 ▼ 0.19%
As of 12/26/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com